Lipodystrophy clinical trials at UCSF
1 in progress, 1 open to new patients
The BROADEN Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Familial Partial Lipodystrophy
open to eligible people ages 18–65
The purpose of this study is to evaluate the efficacy and safety of volanesorsen (IONIS-APOCIIIRx) given for 52 weeks in patients with Familial Partial Lipodystrophy.
San Francisco, California and other locations